Display options
Cite
Liu D, Hou X, Wu W, et al. Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer. Cell Death Dis. 2021;12(8):789doi: 10.1038/s41419-021-04073-0.
Liu, D., Hou, X., Wu, W., Zanfagnin, V., Li, Y., Correia, C., Zhao, Z., Zhao, C., Liu, Z., Zhang, T., Fang, Z., Wang, H., Xu, C., Weroha, S. J., Kaufmann, S. H., & Dai, H. (2021). Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer. Cell death & disease, 12(8), 789. https://doi.org/10.1038/s41419-021-04073-0
Liu, Dongyan, et al. "Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer." Cell death & disease vol. 12,8 (2021): 789. doi: https://doi.org/10.1038/s41419-021-04073-0
Liu D, Hou X, Wu W, Zanfagnin V, Li Y, Correia C, Zhao Z, Zhao C, Liu Z, Zhang T, Fang Z, Wang H, Xu C, Weroha SJ, Kaufmann SH, Dai H. Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer. Cell Death Dis. 2021 Aug 12;12(8):789. doi: 10.1038/s41419-021-04073-0. PMID: 34385422; PMCID: PMC8361168.
Copy Download .nbib Format: NLM
Share it on

Cell Death Dis. 2021 Aug 12;12(8):789. doi: 10.1038/s41419-021-04073-0.

Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer.

Cell death & disease

Dongyan Liu, Xiaonan Hou, Wangyu Wu, Valentina Zanfagnin, Yunjian Li, Cristina Correia, Zhiyang Zhao, Chenggang Zhao, Zhirong Liu, Tao Zhang, Zhiyou Fang, Hongzhi Wang, Chao Xu, Saravut J Weroha, Scott H Kaufmann, Haiming Dai

Affiliations

  1. Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health & Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.
  2. University of Science and Technology of China, Hefei, 230026, China.
  3. Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, 230031, China.
  4. Division of Medical Oncology, Mayo Clinic, Rochester, MN, 55905, USA.
  5. Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China.
  6. School of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, China.
  7. Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA.
  8. Division of Oncology Research, Mayo Clinic, Rochester, MN, 55905, USA.
  9. Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA. [email protected].
  10. Division of Oncology Research, Mayo Clinic, Rochester, MN, 55905, USA. [email protected].
  11. Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health & Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China. [email protected].
  12. Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, 230031, China. [email protected].

PMID: 34385422 PMCID: PMC8361168 DOI: 10.1038/s41419-021-04073-0

Abstract

We previously found that preformed complexes of BAK with antiapoptotic BCL2 proteins predict BH3 mimetic sensitivities in lymphohematopoietic cells. These complexes have not previously been examined in solid tumors or in the context of conventional anticancer drugs. Here we show the relative amount of BAK found in preformed complexes with MCL1 or BCLX

© 2021. The Author(s).

References

  1. Nature. 2016 Oct 27;538(7626):477-482 - PubMed
  2. Nat Commun. 2015 Feb 05;6:6220 - PubMed
  3. Nat Biotechnol. 2012 Feb 19;30(3):283-8 - PubMed
  4. Proc Natl Acad Sci U S A. 2010 May 4;107(18):8352-6 - PubMed
  5. J Clin Invest. 2007 Jan;117(1):112-21 - PubMed
  6. Expert Opin Emerg Drugs. 2020 Jun;25(2):165-188 - PubMed
  7. Anticancer Drugs. 1998 Jan;9(1):51-7 - PubMed
  8. Genes Dev. 2017 Sep 1;31(17):1754-1769 - PubMed
  9. Mol Med Rep. 2016 Mar;13(3):2543-51 - PubMed
  10. Cancer Treat Rep. 1987 Dec;71(12):1171-7 - PubMed
  11. Cell Death Dis. 2015 Jan 15;6:e1590 - PubMed
  12. Mol Cell. 2005 Feb 4;17(3):393-403 - PubMed
  13. Science. 2011 Nov 25;334(6059):1129-33 - PubMed
  14. J Natl Cancer Inst. 1988 Dec 7;80(19):1526-33 - PubMed
  15. Nat Rev Cancer. 2015 Dec;15(12):747-56 - PubMed
  16. Science. 2017 Mar 17;355(6330):1152-1158 - PubMed
  17. Nature. 2009 May 14;459(7244):262-5 - PubMed
  18. F1000Res. 2016 Dec 1;5:2804 - PubMed
  19. Cell Death Dis. 2020 Apr 24;11(4):281 - PubMed
  20. Science. 1999 Nov 26;286(5445):1735-8 - PubMed
  21. Cancer Res. 2016 Aug 15;76(16):4775-84 - PubMed
  22. Cell. 2019 Apr 18;177(3):502-505 - PubMed
  23. Exp Cell Res. 2000 Apr 10;256(1):42-9 - PubMed
  24. Nat Rev Clin Oncol. 2015 Dec;12(12):693-704 - PubMed
  25. Nat Rev Dis Primers. 2016 Aug 25;2:16061 - PubMed
  26. Oncogene. 2019 May;38(22):4352-4365 - PubMed
  27. J Cell Biol. 2011 Jul 11;194(1):39-48 - PubMed
  28. Cell. 2012 Oct 12;151(2):344-55 - PubMed
  29. Adv Enzyme Regul. 1984;22:27-55 - PubMed
  30. Cancer Res. 2008 May 1;68(9):3421-8 - PubMed
  31. J Biol Chem. 2003 Dec 12;278(50):49795-805 - PubMed
  32. Onco Targets Ther. 2019 Dec 16;12:11097-11105 - PubMed
  33. Cancer Cell. 2006 May;9(5):351-65 - PubMed
  34. Cell Death Differ. 2018 Feb;25(2):282-293 - PubMed
  35. Mol Cell. 2008 May 9;30(3):369-80 - PubMed
  36. Ann Oncol. 2021 Jun;32(6):710-725 - PubMed
  37. F1000Res. 2019 Sep 30;8: - PubMed
  38. Mol Cell. 1999 Mar;3(3):287-96 - PubMed
  39. Cancer Res. 1995 Oct 1;55(19):4471-8 - PubMed
  40. Genes Dev. 2015 Oct 15;29(20):2140-52 - PubMed
  41. Nat Rev Cancer. 2007 Aug;7(8):573-84 - PubMed
  42. Nat Rev Cancer. 2003 May;3(5):330-8 - PubMed
  43. Exp Cell Res. 2001 Nov 1;270(2):277-88 - PubMed
  44. Exp Dermatol. 2013 Aug;22(8):518-23 - PubMed
  45. Cancer Res. 1985 Jun;45(6):2741-7 - PubMed
  46. Mol Cell. 2009 Nov 13;36(3):487-99 - PubMed
  47. J Clin Oncol. 2015 Nov 10;33(32):3836-8 - PubMed
  48. Gynecol Oncol. 2016 Nov;143(2):379-388 - PubMed
  49. Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84 - PubMed
  50. J Natl Cancer Inst Monogr. 1993;(15):131-9 - PubMed
  51. Nat Rev Cancer. 2017 Apr;17(4):254-268 - PubMed
  52. J Biol Chem. 2009 Jul 3;284(27):18311-22 - PubMed
  53. J Biol Chem. 2014 Jan 3;289(1):89-99 - PubMed
  54. Cancer Discov. 2015 Jul;5(7):713-22 - PubMed
  55. Clin Cancer Res. 2014 Mar 1;20(5):1288-97 - PubMed
  56. Clin Cancer Res. 2011 Sep 1;17(17):5656-67 - PubMed
  57. Cancer Cell. 2005 Mar;7(3):227-38 - PubMed
  58. Biochem Biophys Res Commun. 2009 Jan 30;379(1):145-50 - PubMed

Publication Types

Grant support